Lytix Biopharma (LYTIX) Q4 2024 earnings summary

Executive summary

• Achieved significant clinical progress, including a 97% objective response rate and 86% tumor size reduction in phase II BCC study with Verrica, and promising interim data in late-stage melanoma with 40% disease control in heavily pre-treated patients; phase III and NeoLIPA studies ongoing.

• Raised NOK 111 million in December 2024, strengthening financial stability, extending the cash runway into 2026, and supporting key milestones.

• Advanced LTX-401 with a new superior formulation, targeting first-in-human trials in 2026.

• Secured a pivotal US patent for LTX-315 in combination with PD-1 inhibitors, enhancing IP protection and commercial value.

• Strengthened management team with the appointment of a new CTO and Executive Director of Clinical Development.

Financial highlights

• Raised NOK 111 million in Q4 2024, increasing cash and short-term investments to NOK 130.8 million at year-end, up from NOK 27.4 million in 2023.

• Total liabilities increased to NOK 39 million at year-end, mainly due to accrued expenses from the ATLAS-IT-05 study.

• Q4 2024 loss from operations was NOK 32.6 million; FY 2024 loss was NOK 94.3 million.

• Revenue for H2 2024 was NOK 3.9 million, mainly from services to Verrica.

• Financial runway extends well into 2026, supporting ongoing and planned clinical programs.

Outlook and guidance

• FDA discussions for LTX-315 in BCC planned for H1 2025, with phase III trial preparations underway.

• Interim results from the NeoLIPA study in early-stage melanoma expected in Q3 2025; top-line results in H1 2026.

• LTX-401 clinical trial launch targeted for 2026, following positive preclinical data and regulatory feedback.

• Focus on strategic partnerships and commercialization to maximize stakeholder value.